XENE241220C50000
- 3.97
- 0.000.00%
Xenon Pharmaceuticals Newsroom
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Xenon to Present at Upcoming Investor Conferences
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $56
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
TD Cowen Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $53 to $60
Express News | Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $46 From $49
Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham
Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Developments Earn a Buy Rating
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript Summary
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
Xenon Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Xenon Pharmaceuticals Reports Q3 EPS (81c), Consensus (81c)
Express News | Xenon Pharmaceuticals Q3 2024 GAAP EPS $(0.81), Inline
Express News | Xenon Pharmaceuticals Q3 Pretax Profit USD -63.11 Million Vs. IBES Estimate USD -63 Million
Xenon Pharmaceuticals 3Q Loss/Shr 81c >XENE
Earnings Preview: Xenon Pharmaceuticals
Earnings Preview: XENE to Report Financial Results Post-market on November 12
Xenon to Report Q3 2024 Financial Results on November 12, 2024